Summit Therapeutics Inc.
SMMTNASDAQHealthcare● Active
$14.53
$-0.24(-1.62%)
Market Cap$11.3B
P/E Ratio—
52W High$30.98
52W Low$13.83
Summit Therapeutics Inc. (SMMT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SMMT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
-$0.24
Est. -$0.33 · +27.3%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
SMMT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.26 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | Apr 30, 2026 | -$0.33 | -$0.24 | +27.3% | — | $0.00B | — |
| ▼ Q1 FY2026 | Feb 23, 2026 | -$0.10 | -$0.29 | -182.5% | — | $0.06B | — |
| ▼ Q4 FY2025 | Oct 20, 2025 | -$0.18 | -$0.31 | -76.4% | — | $0.08B | — |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$0.09 | -$0.76 | -736.9% | — | — | — |
| ▲ Q2 FY2025 | May 1, 2025 | -$0.09 | -$0.09 | +3.3% | — | — | — |
| ▲ Q1 FY2025 | Feb 24, 2025 | -$0.08 | -$0.08 | +2.2% | — | — | — |
| ▼ Q4 FY2024 | Oct 30, 2024 | -$0.07 | -$0.08 | -14.3% | — | — | — |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.26
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Beat
EPS Actual
-$0.24
EPS Est.
-$0.33
EPS Surpr.
+27.3%
Revenue
—
Q1 FY2026
Feb 23, 2026Miss
EPS Actual
-$0.29
EPS Est.
-$0.10
EPS Surpr.
-182.5%
Revenue
—
Q4 FY2025
Oct 20, 2025Miss
EPS Actual
-$0.31
EPS Est.
-$0.18
EPS Surpr.
-76.4%
Revenue
—
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$0.76
EPS Est.
-$0.09
EPS Surpr.
-736.9%
Revenue
—
Q2 FY2025
May 1, 2025Beat
EPS Actual
-$0.09
EPS Est.
-$0.09
EPS Surpr.
+3.3%
Revenue
—
Q1 FY2025
Feb 24, 2025Beat
EPS Actual
-$0.08
EPS Est.
-$0.08
EPS Surpr.
+2.2%
Revenue
—
Q4 FY2024
Oct 30, 2024Miss
EPS Actual
-$0.08
EPS Est.
-$0.07
EPS Surpr.
-14.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.31 | $-0.31 | $-0.31 | 2 |
| Q3 FY2027 | $-0.29 | $-0.29 | $-0.29 | 2 |
| Q2 FY2027 | $-0.28 | $-0.28 | $-0.28 | 2 |
| Q1 FY2027 | $-0.27 | $-0.27 | $-0.27 | 2 |
| Q4 FY2026 | $-0.34 | $-0.34 | $-0.34 | 4 |
| Q3 FY2026 | $-0.28 | $-0.28 | $-0.27 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 6 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 6 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 6 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 6 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 6 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 13 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 30, 2026 | +27.3% | $20.83 | $21.46 | +3.02% |
| ▼ Q1 FY2026 | Feb 23, 2026 | -182.5% | $15.94 | $16.09 | +0.94% |
| ▼ Q4 FY2025 | Oct 20, 2025 | -76.4% | $20.99 | $20.04 | -4.53% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -736.9% | $28.66 | $28.25 | -1.43% |
| ▲ Q2 FY2025 | May 1, 2025 | +3.3% | $24.12 | $24.67 | +2.28% |
| ▲ Q1 FY2025 | Feb 24, 2025 | +2.2% | $22.12 | $18.84 | -14.83% |
| ▼ Q4 FY2024 | Oct 30, 2024 | -14.3% | $21.83 | $18.65 | -14.57% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +16.7% | $10.02 | $9.54 | -4.79% |
Q2 FY2026+3.02%
Report Date
Apr 30, 2026
EPS Beat/Miss
+27.3%
Price Before
$20.83
Price After
$21.46
Q1 FY2026+0.94%
Report Date
Feb 23, 2026
EPS Beat/Miss
-182.5%
Price Before
$15.94
Price After
$16.09
Q4 FY2025-4.53%
Report Date
Oct 20, 2025
EPS Beat/Miss
-76.4%
Price Before
$20.99
Price After
$20.04
Q3 FY2025-1.43%
Report Date
Aug 11, 2025
EPS Beat/Miss
-736.9%
Price Before
$28.66
Price After
$28.25
Q2 FY2025+2.28%
Report Date
May 1, 2025
EPS Beat/Miss
+3.3%
Price Before
$24.12
Price After
$24.67
Q1 FY2025-14.83%
Report Date
Feb 24, 2025
EPS Beat/Miss
+2.2%
Price Before
$22.12
Price After
$18.84
Q4 FY2024-14.57%
Report Date
Oct 30, 2024
EPS Beat/Miss
-14.3%
Price Before
$21.83
Price After
$18.65
Q3 FY2024-4.79%
Report Date
Aug 6, 2024
EPS Beat/Miss
+16.7%
Price Before
$10.02
Price After
$9.54
Avg Beat Reaction-3.58%
Avg Miss Reaction-4.90%
Beat Rate4 / 8 quarters
Largest Move-14.83% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SMMT ends December
Summit Therapeutics Inc. (SMMT) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $-0.24 — beating the analyst consensus of $-0.33 by +27.3%. The next SMMT earnings date is expected around September 1, 2026.
Each quarter, investors track SMMT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SMMT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SMMT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SMMT earnings · 5 questionsSummit Therapeutics Inc.'s next earnings report is expected around September 1, 2026. SMMT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SMMT historically reports after market close (AMC).
SMMT earnings datewhen is SMMT earningsSMMT next earnings datewhen does SMMT report earningsSMMT earnings calendar
▸ Source: FMP · Summit Therapeutics Inc. SEC filings · US GAAP · Summit Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026